Skip to Content
Merck

A2487

Cotrimoxazole

Ready Made Solution, 100 mg/mL in DMSO

Synonym(s):

Trimethoprim-Sulfamethoxazole, TMP-SMX

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H18N4O3 · 5 C10H11N3O3S
CAS Number:
8064-90-2
Molecular Weight:
1556.71
MDL number:
MFCD00242808
UNSPSC Code:
51102829
NACRES:
NA.85

Product Name

Cotrimoxazole, Ready Made Solution, 100 mg/mL in DMSO

SMILES string

[S](=O)(=O)(Nc4n[o]c(c4)C)c3ccc(cc3)N.Nc1nc(c(cn1)Cc2cc(c(c(c2)OC)OC)OC)N

InChI

1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)

InChI key

WZRJTRPJURQBRM-UHFFFAOYSA-N

Quality Level

200

form

liquid
ready-to-use solution

concentration

100 mg/mL in DMSO

color

colorless to faint yellow

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
fungi
parasites

mode of action

DNA synthesis | interferes

shipped in

dry ice

storage temp.

−20°C

Related Categories

Application

Cotrimoxazole has been used as an antimicrobial agent.

Biochem/physiol Actions

Cotrimoxazole, a combination of trimethoprim and sulfamethoxazole, interferes with the cellular metabolism of folic acid in the bacterial cell by blocking the biosynthesis of nucleotides. Trimethoprim binds to dihydrofolate reductase (DHFR) which inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), resulting in an antimicrobial effect. Sulfamethoxazole interferes with the synthesis of nucleic acids in sensitive microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid. The net effect of these actions is to inhibit thymidine synthesis which prevents bacterial DNA synthesis.

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Packaging

1ml

Preparation Note

prepared using a 1:5 mixture of trimethoprim:sulfamethoxazole

pictograms

Health hazard
GHS08

signalword

Warning

Hazard Classifications

Aquatic Chronic 3 - Repr. 2

Storage Class

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000411473
0000383891
0000360729
0000342080
0000383891

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nada A Elnadi et al.
Journal of the Egyptian Society of Parasitology, 43(2), 457-462 (2013-11-23)
Pneumocystitis may cause fatal pneumonia in premature, seriously ill infants at intensive care units. The present study evaluated the routine treatment applied at Sohag pediatrics department for neonatal and infantile pneumonia (in NICU & PICU) on PCP and to compare
Ana I Camargo et al.
Biochimica et biophysica acta, 1834(12), 2823-2831 (2013-10-26)
Centrins are calcium-binding proteins associated with microtubules organizing centers. Members of two divergent subfamilies of centrins were found in the aquatic fungus Blastocladiella emersonii, contrasting with the occurrence of only one member known for the better explored terrestrial fungi. BeCen1
Oana Maria Parasca et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 117(2), 558-564 (2013-12-18)
Sulfonamides and their different derivatives are extensively used in therapy due to their pharmacological properties. Sulfa drugs were amongst the oldest synthesized antimicrobial agents and are still widely used today to treat different microbial infections. Clinical treatment with sulfonamides has
Milind M Baldi et al.
Journal of bronchology & interventional pulmonology, 20(4), 333-337 (2013-10-29)
Pulmonary alveolar proteinosis (PAP) is a rare disease with worldwide distribution and an estimated incidence of 0.36 cases per million. We report a case of a PAP coexisting with Pneumocystis jiroveci pneumonia and Mycobacterium tuberculosis infection. The patient was treated
Désirée Caselli et al.
The Journal of pediatrics, 164(2), 389-392 (2013-11-21)
To determine whether a simplified, 1-day/week regimen of trimethoprim/sulfamethoxazole is sufficient to prevent Pneumocystis (jirovecii [carinii]) pneumonia (PCP). Current recommended regimens for prophylaxis against PCP range from daily administration to 3 consecutive days per week dosing. A prospective survey of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service